Jun 2026 (Q1 FY27) — Aug 6, 2026
Haemonetics Q1 FY27 — Strong Start with Raised Full-Year Guidance
Read the full callHaemonetics (HAE) earnings
- Jun 2026
- Jun 2026 (Q1 FY27)
- Mar 2026
Haemonetics earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 339 | +5.6% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 16.9 | +0.2 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 33.0 | −3.0% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$118.73 +0.38% · +$0.45
Performance +136.2% 1Y
1Y: $50.26 on 17 Oct 2025 → $118.73. High $122.06 (12 Oct 2026), low $49.44 (29 Oct 2025).
- Previous close
- $118.28
- 52-week range
- $49.44 – $122.06
- One year
- +134.14%
Overview
- Symbol
- HAE
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Haemonetics earnings calls (HAE)
Financials
What the filings say
Net profit, year on year: −3% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 346 | 349 | 331 | 321 | 327 | 339 | 346 | 339 |
| Operating profit | 52 | 59 | 71 | 54 | 58 | 67 | -23 | 57 |
| Operating margin | 15.0% | 16.9% | 21.6% | 16.8% | 17.9% | 19.9% | −6.7% | 16.9% |
| Profit before tax | 45 | 50 | 71 | 45 | 51 | 60 | -28 | 48 |
| Tax rate | 24.3% | 24.9% | 18.0% | 24.7% | 24.6% | 25.4% | 29.1% | 30.6% |
| Net profit | 34 | 37 | 58 | 34 | 39 | 45 | -20 | 33 |
| EPS ($ per share) | 0.66 | 0.75 | — | 0.71 | 0.81 | 0.96 | — | 0.73 |
| Line item | Mar 2019 | Mar 2020 | Apr 2021 | Apr 2022 | Apr 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 |
| Reserves | 161 | 79 | 158 | 202 | 253 | 360 | 352 | 279 |
| Total liabilities | 607 | 680 | 1,088 | 1,110 | 1,117 | 1,236 | 1,630 | 1,600 |
| Fixed assets | 344 | 253 | 218 | 258 | 311 | 311 | 284 | 306 |
| Total assets | 1,275 | 1,267 | 1,820 | 1,860 | 1,935 | 2,196 | 2,451 | 2,396 |
| Line item | Mar 2019 | Mar 2020 | Apr 2021 | Apr 2022 | Apr 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 159 | 158 | 109 | 172 | 273 | 182 | 182 | 293 |
| Cash from investing | -116 | -57 | -425 | -86 | -144 | -322 | -162 | -180 |
| Cash from financing | -51 | -131 | 367 | -16 | -100 | 38 | 109 | -178 |
| Net cash flow | -11 | -32 | 55 | 67 | 25 | -106 | 128 | -61 |
| Capital expenditure | -119 | -49 | -37 | -97 | -191 | -38 | -39 | -33 |
| Free cash flow | 40 | 109 | 72 | 76 | 82 | 144 | 142 | 260 |
HAE revenue by segment
| Segment | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Q4 FY2026 | Q1 FY2027 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Apheresis | — | — | — | — | — | — | — | 56% | — |
| Med Surg | — | — | — | — | — | — | — | 44% | — |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
Revenue by region
Q1 FY2027 · share of revenue
- US 76% ↑ 2 pt
- Europe 13% ↑ 1 pt
- Asia 6% ↓ 2 pt
- JP 4% ↓ 1 pt
- Other Countryor Region 1% ↓ 1 pt
As HAE cuts its regions in its filings; they can nest, so they need not add to 100%.
Insider filings
27 filings between Oct 31, 2025 and Jul 24, 2026.
Open market
decisions to buy or sellPurchases
$98.8K
1 purchase by 1 insider
Sales
None
No insider sold shares.
Compensation
not trading decisions- 15
- Award — granted as compensation
- 11
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| KROLL MARK W | $98.8K | — | Nov 10, 2025 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Jul 24, 2026 | Bryant Diane M Director | Award | 2,538 | — |
| Jul 24, 2026 | COYLE MICHAEL J Director | Award | 2,538 | — |
| Jul 24, 2026 | Johnson Lloyd Emerson Director | Award | 2,538 | — |
| Jul 24, 2026 | KROLL MARK W Director | Award | 2,538 | — |
| Jul 24, 2026 | Pomeroy Claire Director | Award | 2,538 | — |
| Jul 24, 2026 | Zane Ellen M Director | Award | 2,538 | — |
| Jul 24, 2026 | Madaus Martin D Director | Award | 2,538 | — |
| Jul 24, 2026 | ABERNATHY ROBERT E Director | Award | 2,538 | — |
| Jun 5, 2026 | Miller Laurie A. SVP, Human Resources | Tax withheld | 313 | $22.3K |
| Jun 5, 2026 | Maunsell Farris Maryanne VP, Chief Accounting Officer | Tax withheld | 259 | $18.5K |
| May 15, 2026 | Simon, Christopher President & CEO | Tax withheld | 9,681 | $544.9K |
| May 15, 2026 | Simon, Christopher President & CEO | Award | 78,344 | — |
| May 15, 2026 | Miller Laurie A. SVP, Human Resources | Tax withheld | 948 | $53.4K |
| May 15, 2026 | Miller Laurie A. SVP, Human Resources | Award | 13,323 | — |
| May 15, 2026 | Galvin Roy EVP, Chief Commercial Officer | Tax withheld | 879 | $49.5K |
| May 15, 2026 | Galvin Roy EVP, Chief Commercial Officer | Award | 27,535 | — |
| May 15, 2026 | Maunsell Farris Maryanne VP, Chief Accounting Officer | Tax withheld | 197 | $11.1K |
| May 15, 2026 | Maunsell Farris Maryanne VP, Chief Accounting Officer | Award | 2,220 | — |
| May 15, 2026 | DArecca James EVP, Chief Financial Officer | Tax withheld | 2,505 | $141.0K |
| May 15, 2026 | DArecca James EVP, Chief Financial Officer | Award | 29,312 | — |
| May 15, 2026 | Chan Frank EVP, Chief Operating Officer | Tax withheld | 546 | $30.7K |
| May 15, 2026 | Chan Frank EVP, Chief Operating Officer | Award | 27,535 | — |
| May 15, 2026 | Basil Michelle L EVP and General Counsel | Tax withheld | 2,913 | $164.0K |
| May 15, 2026 | Basil Michelle L EVP and General Counsel | Award | 28,424 | — |
| May 1, 2026 | DArecca James EVP, Chief Financial Officer | Tax withheld | 655 | $38.8K |
| Nov 10, 2025 | KROLL MARK W Director | Purchase | 1,400 | $98.8K |
| Oct 31, 2025 | Galvin Roy EVP, Chief Commercial Officer | Tax withheld | 145 | $7.3K |
| Sep 17, 2025 | Miller Laurie A. SVP, Human Resources | Tax withheld | 238 | $11.9K |
| Jul 24, 2025 | Zane Ellen M Director | Award | 2,693 | — |
| Jul 24, 2025 | ABERNATHY ROBERT E Director | Award | 2,693 | — |
| Jul 24, 2025 | Bryant Diane M Director | Award | 2,693 | — |
| Jul 24, 2025 | COYLE MICHAEL J Director | Award | 2,693 | — |
| Jul 24, 2025 | Dockendorff Charles J Director | Award | 2,693 | — |
| Jul 24, 2025 | Johnson Lloyd Emerson Director | Award | 2,693 | — |
| Jul 24, 2025 | KROLL MARK W Director | Award | 2,693 | — |
| Jul 24, 2025 | Pomeroy Claire Director | Award | 2,693 | — |
| Jun 5, 2025 | Maunsell Farris Maryanne VP, Chief Accounting Officer | Award | 2,662 | — |
| Jun 5, 2025 | Miller Laurie A. SVP, Human Resources | Award | 3,195 | — |
| May 30, 2025 | Simon, Christopher President & CEO | Tax withheld | 26,234 | $1.82M |
| May 30, 2025 | Basil Michelle L EVP and General Counsel | Award | 15,554 | $0 |
| May 30, 2025 | Basil Michelle L EVP and General Counsel | Tax withheld | 7,469 | $518.2K |
| May 30, 2025 | DArecca James EVP, Chief Financial Officer | Award | 12,221 | $0 |
| May 30, 2025 | DArecca James EVP, Chief Financial Officer | Tax withheld | 5,864 | $406.8K |
| May 30, 2025 | Miller Laurie A. SVP, Human Resources | Tax withheld | 2,283 | $158.4K |
| May 30, 2025 | Miller Laurie A. SVP, Human Resources | Award | 7,777 | $0 |
| May 30, 2025 | Simon, Christopher President & CEO | Award | 66,666 | $0 |
| May 16, 2025 | Galvin Roy EVP, Chief Commercial Officer | Award | 5,689 | — |
| May 16, 2025 | Basil Michelle L EVP and General Counsel | Award | 6,755 | — |
| May 16, 2025 | Simon, Christopher President & CEO | Award | 21,405 | — |
| May 16, 2025 | DArecca James EVP, Chief Financial Officer | Award | 7,111 | — |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for HAEMONETICS CORP
Free account. Everything above stays public.
Write why you follow HAEMONETICS CORP and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading